Patau Syndrome (trisomy 13) occurs in approximately 1 in 16000 live births. It is caused by an additional chromosome 13 or extra chromosome 13 material. The features commonly associated with trisomy 13 include a number of midline defects such as cleft lip and palate, holoprosencephaly, microphthalmia and hypertelorism, (small, wide-spaced eyes) and microcephaly (small head). Also common are extra fingers and/or toes, hypotonia, heart, brain, and spinal cord abnormalities. Approximately 80% of infants born with trisomy 13 do not survive the first month of life. The majority of cases are “free” trisomy 13, but in approximately 20% of cases the additional chromosome 13 material is derived from a translocation, which may or may not be inherited from a parent. Although free trisomy 13 occurs sporadically, there is an increased risk of a Patau syndrome pregnancy with increasing maternal age. Trisomy 13 may also appear in a mosaic form, where normal cells are also present in the individual. These individuals may exhibit a milder phenotype, which is dependent on the extent and tissue distribution of the normal cell line.
For prenatal referrals we accept samples from women that have a high risk (>1:150) following antenatal screening including Combined or Quadruple testing, a family history of a chromosome rearrangement predisposing to trisomy 13, a previously affected pregnancy, or ultrasound scan findings indicative of trisomy 13. For postnatal samples we accept referrals from patients with appropriate clinical features for a diagnosis of trisomy 13 or for the confirmation of a prenatal diagnosis.
Price & reporting times
NHS referrals to this service are paid for where there is an existing specialist commissioning contract for genetic testing. In other cases please contact the lab for prices.
|Test||Price (£ ex VAT)||TRT *|
|G-banded neonatal chromosome analysis||POA||10 cd|
|G-banded prenatal chromosome analysis||POA||14 cd|
|Prenatal or neonatal microarray analysis||POA||14 cd|
Test validation & quality assurance - information for users
The QF-PCR test is for trisomy 13, 18, 21, only and will not detect mosaicism or structural rearrangements. Rarely, testing may be uninformative or fail to give a result either due to maternal cell contamination or other factors. Maternal and paternal blood samples may be requested to help interpret results. Microarray analysis will not detected balanced rearrangements and may not detect mosaicism. Maternal cell contamination is excluded for prenatal samples prior to microarray testing by analysis of a maternal blood sample. This laboratory participates in the CEQAS quality assessment scheme for this test.
Pre-natal (serum screening): amniotic fluid (minimum 10ml)/chorionic villus biopsy (CVB) (minimum 10mg) sample plus 4ml EDTA maternal blood sample
Please see our referral guidelines for more information.